Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Stomach Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Appendiceal Neoplasms 1

Interventions

niraparib 4olaparib 2apatinib 2Sevoflurane 2Saline Solution 2Propofol 2Carboplatin 2Bevacizumab 2pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1palbociclib 1liposomal doxorubicin 1lenvatinib 1gadofosveset trisodium 1fosaprepitant 1ferrous fumarate 1Tranexamic Acid 1Trabectedin 1Sunitinib 1Sodium Chloride 1Pharmacokinetics 1Patient-Specific Modeling 1Pafolacianine 1Paclitaxel 1LY 353381 1Injections 1Indocyanine Green 1Folic Acid 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Ovarian Neoplasms × Pafolacianine × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡